Genmab ASMEX:GMABN 92 Current Ratio is 2.18 as of Mar. 2026, which is 83% below its 10-year median of 13.08. GuruFocus rates MEX:GMABN with a GF Score™ of 92/100 and a GF Value™ of MXN5,328.99 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Genmab AS ranks worse than 66.1% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Genmab AS's current ratio for the quarter that ended in Mar. 2026 was 2.18.
Genmab AS has a current ratio of 2.18. It generally indicates good short-term financial strength.
The historical rank and industry rank for Genmab AS's Current Ratio or its related term are showing as below:
MEX:GMABN'
s Current Ratio Range Over the Past 10 Years
Min: 2.02 Med: 13.08 Max: 23.99
Current: 2.18
During the past 13 years, Genmab AS's highest Current Ratio was 23.99. The lowest was 2.02. And the median was 13.08.
MEX:GMABN's Current Ratio is ranked worse than 66.1% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs MEX:GMABN: 2.18
Genmab AS (MEX:GMABN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Genmab AS Current Ratio Related Terms
Genmab AS Current Ratio Historical Data
* Premium members only.
The historical data trend for Genmab AS's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GMABN vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Genmab AS's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Current Ratio distribution charts can be found below:
* The bar in red indicates where Genmab AS's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (MEX:GMABN) has a Current Ratio of 2.18 as of Mar. 2026. This is 83% below median its historical median of 13.08. Over the past decade, Genmab AS's Current Ratio has ranged from 2.02 to 23.99. According to the industry distribution chart, Genmab AS ranks #936 out of 1416 companies in the Biotechnology industry, placing it in the top 66.1%.
Is Genmab AS's Current Ratio too high?
Genmab AS's current Current Ratio of 2.18 is 83% below median its 10-year median of 13.08. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 23.99. The Biotechnology industry median Current Ratio is 3.89. Genmab AS's value of 2.18 is 43.9% below this industry median. Based on the distribution chart, Genmab AS ranks #936 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #936 out of 1416 companies for Current Ratio. This places Genmab AS in the lower half of its industry. The industry median Current Ratio is 3.89. Genmab AS's value of 2.18 is 43.9% below this benchmark. Historically, Genmab AS's own Current Ratio has ranged from 2.02 to 23.99 over the past decade. While the company's 10-year median is 13.08 vs. the industry median of 3.89, Genmab AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Current Ratio of 2.18 is 43.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Current Ratio is 2.18, which is 83% below median its own 10-year median of 13.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current Current Ratio is 2.18, which is 83% below median its 10-year median of 13.08 and 43.9% below the Biotechnology industry median of 3.89. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Current Ratio is 2.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (MEX:GMABN) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for MEX:GMABN:
Current Ratio: 2.18 (83% below median its 10-year median of 13.08)
GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
Industry Position: 43.9% below the Biotechnology median (#936 of 1416)
No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score
Get the complete analysis for MEX:GMABN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GMABN has been successfully added to your 
